SCHEMBL5365979

SCHEMBL5365979

CCOC(=O)c1c(C)[nH]c(C=C2C(=O)Nc3ccc(NC(=N)N)cc32)c1C

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 8/20 0.66
PDGFRB P09619 3/20 0.66
ALK Q9UM73 2/20 0.66
FGFR1 P11362 2/20 0.66
ABL1 P00519 1/20 0.66
RET P07949 1/20 0.66
CSF1R P07333 1/20 0.58
AKT2 P31751 3/20 0.57
PRKAA2 P54646 3/20 0.51
PRKAA1 Q13131 3/20 0.51
KDR P35968 7/20 0.51
FLT4 P35916 4/20 0.51
KIT P10721 3/20 0.51
TLK2 Q86UE8 1/20 0.51
LRRK2 Q5S007 1/20 0.51
AURKA O14965 1/20 0.51
MET P08581 1/20 0.51
AURKB Q96GD4 1/20 0.51
AURKC Q9UQB9 1/20 0.51
EGFR P00533 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5359118 0.93 FLT3 (0.68) FLT3PDGFRBALKFGFR1ABL1
SCHEMBL5365610 0.86 PDGFRB (0.69) FLT3PDGFRBALKFGFR1ABL1
SCHEMBL5363278 0.85 PDGFRB (0.68) FLT3PDGFRBALKFGFR1ABL1
SCHEMBL5384496 0.85 FLT3 (0.62) FLT3PDGFRBALKFGFR1ABL1
SCHEMBL31727096 0.84 PDGFRB (0.74) FLT3PDGFRBALKFGFR1ABL1
SCHEMBL19255670 0.84 PDGFRB (0.77) FLT3PDGFRBALKFGFR1ABL1
SCHEMBL5373629 0.83 PDGFRB (0.76) FLT3PDGFRBALKFGFR1ABL1
SCHEMBL5363073 0.82 PDGFRB (0.71) FLT3PDGFRBALKFGFR1ABL1
SCHEMBL5359307 0.82 PDGFRB (0.71) FLT3PDGFRBALKFGFR1ABL1
SCHEMBL5376617 0.82 PDGFRB (0.74) FLT3PDGFRBALKFGFR1ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed
EP-1247803-A2 Indolinone compounds suitable for modulation of protein kinases Sugen, Inc. (US) 2002-10-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK FLT3 395/4885PDGFRB 52/4885ALK 325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.